

An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types

Wai Hoong Chang¹ and Alvina G. Lai¹✉

¹Institute of Health Informatics, University College London, 222 Euston Road, London NW1 2DA, United Kingdom

The AMP-activated protein kinase (AMPK) is an evolutionarily conserved regulator of cellular energy homeostasis. As a nexus for transducing metabolic signals, AMPK cooperates with other energy-sensing pathways to modulate cellular responses to metabolic stressors. With metabolic reprogramming being a hallmark of cancer, the utility of agents targeting AMPK has received continued scrutiny and results have demonstrated conflicting effects of AMPK activation in tumorigenesis. Harnessing multi-omics datasets from human tumors, we seek to evaluate the seemingly pleiotropic, tissue-specific dependencies of AMPK signaling dysregulation. We interrogated copy number variation and differential transcript expression of 92 AMPK pathway genes across 21 diverse cancers involving over 18,000 patients. Cox proportional hazards regression and receiver operating characteristic analyses were used to evaluate the prognostic significance of AMPK dysregulation on patient outcomes. A total of 24 and seven AMPK pathway genes were identified as having loss- or gain-of-function features. These genes exhibited tissue-type dependencies, where survival outcomes in glioma patients were most influenced by AMPK inactivation. Cox regression and log-rank tests revealed that the 24-AMPK-gene set could successfully stratify patients into high- and low-risk groups in glioma, sarcoma, breast and stomach cancers. The 24-AMPK-gene set could not only discriminate tumor from non-tumor samples, as confirmed by multidimensional scaling analyses, but is also independent of tumor, node and metastasis staging. AMPK inactivation is accompanied by the activation of multiple oncogenic pathways associated with cell adhesion, calcium signaling and extracellular matrix organization. Anomalous AMPK signaling converged on similar groups of transcriptional targets where a common set of transcription factors were identified to regulate these targets. We also demonstrated crosstalk between pro-catabolic AMPK signaling and two pro-anabolic pathways, mammalian target of rapamycin and peroxisome proliferator-activated receptors, where they act synergistically to influence tumor progression significantly. Genetic and transcriptional aberrations in AMPK signaling have tissue-dependent pro- or anti-tumor impacts. Pan-cancer investigations on molecular changes of this pathway could uncover novel therapeutic targets and support risk stratification of patients in prospective trials.

Correspondence: alvina.lai@ucl.ac.uk

Introduction

The AMP-activated protein kinase (AMPK) is an evolutionarily conserved key player responsible for energy sensing and homeostasis. Orthologous copies of AMPK prevail universally as heterotrimeric complexes where the human genome encodes two genes for the α catalytic subunit, two β regulatory subunit genes and three γ subunit genes. Historically, AMPK was discovered as a crucial regulator of lipid metabolism(1). Since then, AMPK is implicated in a wide variety of fundamental metabolic processes as well as in metabolic diseases such as cancer and diabetes(2). The first link between AMPK and cancer was identified through the tumor-suppressive function of LKB1, which is upstream of the mTOR pathway(3). The tumor-suppressive roles of AMPK were pharmacologically demonstrated by the application of metabolic inhibitors such as the anti-diabetic metformin and the mimetic of AMP, AICAR(4–6). Numerous studies have since compellingly established the promiscuous nature of these pharmacological agents, whereby the inhibition of cancer cell proliferation occurs through non-specific AMPK-independent avenues(7, 8).

In contrast to the tumor-suppressive results from pharmacological studies, genetic experiments on cancer cells have credibly demonstrated that AMPK activation is crucial for tumor progression and survival(9–12). A myriad of metabolic stressors, such as oxygen deprivation, nutrient starvation and oxidative stress, exists within the tumor microenvironment. Metabolic reprogramming during carcinogenesis would thus trigger AMPK activation to enable cells to survive under conditions of stress typically found in the tumor microenvironment, hence conferring an overall tumor-promoting effect. AMPK is also shown to support cancer growth and migration through crosstalk with other pro-oncogenic pathways. For instance, overexpression of oncogenes MYC and SRC or the loss of the tumor suppressor folliculin could lead to AMPK activation(13–17).

Genetic and pharmacological studies have paved the way for our understanding of the function of AMPK in cancer. However, anti- and pro-neoplastic features of AMPK remain controversial potentially due to the oversimplification of AMPK-modulated processes in in vitro and non-human in-vivo models. The genetic and clinical landscape of AMPK signaling has not been systematically investigated. Thus, our study aims to address an unmet need to rigorously investigate the role of AMPK in diverse cellular context using multi-omics data from actual tumors where we examined somatic copy number alterations, transcriptional and clinical profiles of tumors from 21 cancer types. Our analyses of clinical samples at scale would complement evidence from pharmacological and genetic studies to better elucidate the multi-faceted and cell-specific nature of AMPK signaling on tumor progression.

Methods

AMPK pathway genes and cancer cohorts: 92 AMPK pathway genes were retrieved from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Table S1). Clinical, genomic and transcriptomic datasets of 21 cancers involving over 18,484 patients were downloaded from The Cancer Genome Atlas (TCGA)(18).

Copy number variation, differential expression, multidimensional scaling and survival analyses: Detailed methods of the above analyses were previously published and thus will not be repeated here as per the journal guidelines(19, 20). To summarize, discrete amplification and deletion indicators for copy number variation analyses were obtained from GISTIC gene-level tables(21). GISTIC values of +1 and -1 were annotated as shallow amplification and shallow deletion (heterozygous) events respectively. GISTIC values of +2 and -2 were annotated as deep amplification and deep (homozygous) deletion events respectively. Multidimensional scaling analyses and permutational multivariate analysis of variance (PERMANOVA) were performed using the R vegan package. Survival analyses were performed using Cox proportional hazards regression and the log-rank test. Sensitivity and specificity of the 24-AMPK-gene set were assessed using receiver operating characteristic analyses. Differential expression analyses were performed on patients stratified into high- (4th quartile) and low- (1st quartile) expressing groups using the 24-gene-set to determine the transcriptional effects of anomalous AMPK signaling.

Pathway and transcription factor analyses: Genes that were differentially expressed (DEGs) between the 4th and 1st quartile patient groups were mapped to KEGG, Gene Ontology and Reactome databases using g:profiler(22) to ascertain biological processes and signaling pathways that were enriched. The Enrichr tool(23, 24) was used to map DEGs to the ChEA and ENCODE transcription factor (TF) databases to identify TFs that were significantly enriched as regulators of the DEGs.

Calculating the 24-AMPK-gene score, peroxisome proliferator-activated receptors (PPAR) score and mammalian target of rapamycin (mTOR) score: AMPK scores were calculated from the mean expression of the following genes: SLC2A4, FOXO3, PPP2CB, PIK3CD, CAB39L, CCNA1, FBP1, FBP2, FOXO1, HMGCR, IRS2, PIK3R1, SIRT1, TBC1D1, PPARGC1A, PPP2R2C, MLYCD, PFKFB3, PPP2R2B, PRKAA2, LEPR, CAB39, IRS1 and PFKFB1. PPAR scores for each patient were calculated by taking the mean expression of PPAR signature genes: PLIN5, PPARG, ACADM, GK, CPT2, SCP2, ACAA1, APOA1, PPARA, ACOX2, ANGPTL4, FABP3, PLIN2, AQP7, ACSL1, FABP5, ACADL, and PCK2(20). mTOR/PI3K/AKT scores for each patient were calculated using the following equation: $mTOR/PI3K/AKT \text{ score} = AKT + mTOR + GSK3 + S6K + S6 - PTEN$ (25).

Results

Pan-cancer genomic and transcriptional alterations of AMPK pathway genes

Focusing on the genomic and transcriptomic landscape of 92 genes associated with AMPK signaling retrieved from KEGG across 21 cancer types involving 18,484 patients (Table S1), we interrogated somatic copy number alterations (SCNA) and mRNA expression. To determine the effects of genomic alterations in AMPK pathway genes, we classified genes as having high-level amplifications (gains), low-level amplifications, deep (homozygous) deletions and shallow (heterozygous) deletions. To evaluate pan-cancer patterns of SCNAs, we considered genes that were gained or lost in at least 20% of samples within a cancer type and in at least one-third of cancer types, i.e., at least seven cancer types. A total of 46 genes were recurrently amplified, while 49 genes were recurrently lost (Figure 1; Table S2). AMPK is the central regulator of cellular energy levels, which controls a number of downstream targets, an example being the nuclear receptor HNF4A. Remarkably, HNF4A was found to be the most amplified gene; identified as being recurrently amplified in >20% of samples in all 21 cancers (Figure 1; Table S2). This is followed by CFTR (18 cancer types) and four other genes that were amplified in 17 cancer types (ADIPOR2, LEP, PRKAG2 and RHEB) (Figure 1; Table S2). In contrast, PPP2R2A was the most deleted gene found in >20% of samples across 17 cancers, followed by the deletion of SLC2A4 in 16 cancers and five additional genes (FOXO3, PPP2CB, PPP2R2D, PPP2R5C and PPP2R5E) in 15 cancer types (Figure 1; Table S2). Among all cancer types, the highest number of amplified AMPK pathway genes was observed in esophageal carcinoma (ESCA; 44 genes) followed by bladder cancer (BLCA; 42 genes) and lung cancer (41 genes in both lung squamous cell carcinoma [LUSC] and adenocarcinoma [LUAD]) (Figure 1). Glioma tumors (GBMLGG), in contrast, had only five genes that were recurrently amplified (Figure 1). In terms of somatic deletions, LUSC and ESCA both had 49 genes deleted while no recurrent deletions were observed in papillary renal cell carcinoma (KIRP) (Figure 1).




Fig. 1. The landscape of somatic copy number alterations of AMPK pathway genes. Heatmaps depict (A) fraction of samples within each cancer type that harbor somatic deletions and (B) somatic amplifications. Forty-nine genes are recurrently deleted in at least 20% of tumors within each cancer and in at least seven cancer types. Forty-six genes are recurrently amplified in at least 20% of tumors within each cancer and in at least seven cancer types. Stacked bar charts on the y-axes illustrate the fraction of samples that possess copy number variation of a gene under consideration grouped by shallow and deep deletions or amplifications. Stacked bar charts on the x-axes illustrate the fraction of samples within each cancer type that contain shallow and deep deletions or amplifications. The bar charts on the right of each heatmap depict the number of cancer types with at least 20% of samples affected by gene deletions and amplifications. The Venn diagrams demonstrate the identification of 24 putative loss- and seven gain-of-function genes from gene sets that are somatically altered and differentially expressed. Cancer cohorts analyzed with corresponding TCGA abbreviations are listed in parentheses: bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), glioma (GBMLGG), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), pan-kidney cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), sarcoma (SARC), stomach adenocarcinoma (STAD), stomach and esophageal carcinoma (STES) and uterine corpus endometrial carcinoma (UCEC).


We reasoned that SCNAs associated with transcriptional alterations could be considered as putative gain- or loss-of-function events. Differential expression analyses between tumor and non-tumor samples in each cancer revealed that 15 and 39 genes were significantly upregulated and downregulated in at least seven cancer types respectively (Figure S1). Of these differentially expressed genes, seven and 24 genes were also recurrently amplified and deleted respectively (Venn diagram in Figure 1). Both gene sets were mutually exclusive, i.e., the genes either had gain-or-function or loss-of-function features, but not both.

Molecular underpinnings of patient survival involving putative loss-of-function AMPK pathway components

We next investigated the impact of transcriptional dysregulation of the putative gain- and loss-of-function genes identified previously on patient survival outcomes across all cancer types. Employing Cox proportional hazards regression, we observed that all 31 genes (seven gain-of-function and 24 loss-of-function genes), were prognostic in at least one can-

cer type (Figure 2A). The highest number of prognostic genes was observed in glioma (GBMLGG) tumors (26/31 genes), while none of the 31 genes were significantly associated with overall survival outcomes in ESCA and cholangiocarcinoma (CHOL) (Figure 2A). Intriguingly, although ESCA had the highest number of SCNAs (Figure 1), none of the genes harbored prognostic information, suggesting that alterations in AMPK signaling components have minimal roles in driving tumor progression and patient outcomes. FBP1 was significantly associated with overall survival outcomes in 10 cancers while PPP2R2C and PPP2R2B in 8 cancers (Figure 2A). FBP2 is the least prognostic gene in only one cancer type, cervical squamous cell carcinoma and endocervical adenocarcinoma; CESC (Figure 2A).

Given the prevalence of loss-of-function phenotypes in determining clinical outcomes (Figure 2A), we proceeded to examine the combined impact of all 24 loss-of-function genes on patient survival and oncogenic dysregulation. To determine the extent of AMPK pathway variation across the 21 cancers, we calculated ‘pathway scores’ for each of the



18,484 tumor samples by taking the mean transcript expression values of the 24 genes: SLC2A4, FOXO3, PPP2CB, PIK3CD, CAB39L, CCNA1, FBP1, FBP2, FOXO1, HMGCR, IRS2, PIK3R1, SIRT1, TBC1D1, PPARGC1A, PPP2R2C, MLYCD, PFKFB3, PPP2R2B, PRKAA2, LEPR, CAB39, IRS1 and PFKFB1. We observed interesting patterns when cancers were ranked from low to high, based on their median pathway scores (Figure 2B). GBMLGG had the highest median pathway score, while BLCA and CESC were found at the lower end of the spectrum (Figure 2B). As expected, Kaplan-Meier analysis revealed a significant difference in overall survival between glioma patients ($P < 0.0001$) stratified by low and high 24-gene pathway scores (Figure 2C). Interestingly, the contribution of AMPK

signaling in cancer prognostication is cancer-type dependent. As in glioma, log-rank tests revealed that patients with high 24-gene scores had significantly improved survival outcomes in breast cancer ($P = 0.0026$) and sarcoma ($P = 0.021$) (Figure 2C). In contrast, high expression of the 24 genes was associated with increased mortality rates in stomach adenocarcinoma ($P = 0.033$) (Figure 2C). These results were in agreement when independently validated using the Cox regression approach: breast (hazard ratio [HR] = 0.397; $P = 0.0028$), glioma (HR = 0.430; $P < 0.0001$), sarcoma (HR = 0.379; $P = 0.021$) and stomach (HR = 1.825; $P = 0.034$) cancers (Table S3). Since the 24-gene score could be used to stratify patients into high- and low-risk groups, we predict that when considered together, gene




Fig. 3. The 24-AMPK-gene set is independent of tumor stage and histological subtype. (A) Kaplan-Meier analyses of patients grouped by tumor, node and metastasis (TNM) stage (breast and stomach cancers) or by the histological subtype of leiomyosarcoma and the 24-gene score. For leiomyosarcoma, the log-rank test reveals a significant difference in survival rates between 1st and 4th quartile patients. (B) Receiver-operating characteristic (ROC) analyses on the 5-year predictive performance of the 24-gene set. ROC curves generated by the 24-gene set are compared to curves generated from both 24-gene set and TNM staging, where available, or histological subtype. AUC: area under the curve.

expression values could discriminate tumor from non-tumor samples. Although analysis could not be performed on sarcoma (this dataset only had two non-tumor samples), multidimensional scaling analyses and PERMANOVA tests of breast ($P < 0.001$), glioma ($P < 0.001$) and stomach ($P < 0.001$) cancers revealed significant separation between tumor and non-tumor samples in two-dimensional space (Figure 2D). Overall, this suggests that the 24-gene set could be harnessed as a diagnostic biomarker for early cancer detection.

To determine the independence of the 24-gene set from other clinicopathological features, we employed multivariate Cox regression and observed that the 24-gene set is independent of tumor, node and metastasis (TNM) staging (where available) in breast (HR = 0.403; $P = 0.0043$) and stomach cancers (HR = 1.835; $P = 0.038$) (Table S3). Similarly, Kaplan-Meier analyses and log-rank tests confirmed that the 24-gene set allowed further risk stratification of patients with tumors of the same TNM stage: breast ($P < 0.0001$) and stomach ($P =$

0.022) (Figure 3A). Furthermore, we observed that within a histological subtype of sarcoma, leiomyosarcoma, patients with elevated AMPK signaling had significantly better survival outcomes ($P = 0.0072$) (Figure 3A); consistent with our previous observation that high pathway scores were associated with good prognosis in sarcoma (Figure 2C).

We next explored the predictive performance (sensitivity versus specificity) of the 24-gene set in all four cancer types using receiver operating characteristic analysis. The area under the ROC curve (AUC) is an indication of how well the gene set could predict patient survival, which ranges from 0.5 to 1. We found that the combined model uniting both 24-gene set and TNM staging outperformed the 24-gene set when considered on its own in breast cancer patients (AUC = 0.749 vs. 0.699) (Figure 3B). Since the AUC for TNM staging was only marginally higher than 0.5 in stomach cancer (AUC = 0.561) while the AUC for the 24-gene set was 0.700, TNM staging did not contribute to any increase




Fig. 4. AMPK inactivation drives oncogenic transcriptional alterations in diverse biological processes and signaling modules. (A) Venn diagram illustrates the number of differentially expressed genes (DEGs) between 1st and 4th quartile patients, as stratified using the 24-AMPK-gene set, in four cancer types. A total of 122 DEGs were common in all four cancers. (B) Dot plots depict the number of significantly enriched pathways and biological processes upon the mapping of DEGs to KEGG, Gene Ontology and Reactome databases. Each dot represents an enriched event. (C) Ontologies that exhibit similar patterns of enrichment across four cancers are shown. DEGs are also mapped to ENCODE and ChEA transcription factor (TF) databases to determine enriched TF binding associated with DEGs.

in performance of the gene set (Figure 3B). AUCs of the 24-gene set in glioma and sarcoma were 0.840 and 0.757 respectively (Figure 3B). Within the leiomyosarcoma histological subtype, AUC was even higher at 0.869 (Figure 3B).

Oncogenic transcriptional alterations associated with AMPK pathway inactivation

AMPK pathway inactivation was associated with altered survival outcomes in patients (Figure 2 and 3). We predict that this could be due to broad transcriptional dysregulation arising from abnormal AMPK signaling. To investigate this phenomenon, we performed differential expression analyses between patients stratified by the 24-gene set into high (4th quartile) and low (1st quartile) expression groups and found that an outstanding number of 122 common genes that were significantly differentially expressed in all four cancer types (Figure 4A). The highest number of differentially expressed genes (DEGs) was observed in stomach cancer (2,496 genes), followed by sarcoma (1,842 genes), glioma (1,523 genes) and breast cancer (1,086 genes) (Figure 4A; Table S4). The DEGs were mapped to KEGG, Gene Ontology and Reactome databases to determine whether they were associated with any functionally enriched pathways. Intriguingly, all four cancer types share similar patterns of functional enrichments (Figure 4B and 4C). For instance, biological processes associated with cell communication, signal transduction, cell differentiation, cell signaling, cell adhesion and cell morphogenesis were enriched in all four cancers (Figure 4C). In terms of specific signaling pathways, calcium signaling, cAMP signaling, and processes associated with extracellular matrix organization were among the most enriched (Figure 4C).

To further identify potential transcriptional regulators of the DEGs, we mapped the DEGs to ENCODE and ChEA transcription factor (TF) binding databases. Remarkably, we identified common TFs, shared across all four cancers, that were implicated as direct binding partners of the DEGs (Figure 4C). Five TFs, SUZ12, SMAD4, REST, EZH2 and NFE2L2, were found to be enriched in all four cancers, suggesting that transcriptional dysregulation of tumors with aberrant AMPK signaling involved direct physical associations of these TFs with target DEGs (Figure 4C). Curiously, FOXM1 and E2F4 were enriched only in glioma tumors, which deserves further exploration in the next section. Overall, our analyses demonstrated that impaired AMPK signaling resulted in common patterns of oncogenesis, which affect the severity of cancer and consequently, mortality rates in patients.


Downstream targets of EZH2, NFE2L2, REST, SMAD4 and SUZ12 were associated with survival outcomes

Pathways modulating energy homeostatic may transduce signals to influence other cognate signaling modules. EZH2, NFE2L2, REST, SMAD4 and SUZ12 were all implicated

as common transcriptional regulators of DEGs in glioma, sarcoma, breast and stomach cancers, suggesting that altered AMPK signaling converged on similar groups of transcriptional targets. Of all the target DEGs of the aforementioned TFs, 8, 10, 24, 12 and 48 genes were found to be common targets of EZH2, NFE2L2, REST, SMAD4 and SUZ12 respectively in all four cancers (Figure 5A). Concatenating all five gene sets yielded 71 unique genes, i.e., genes that were binding targets of more than one TF were considered only once. To gain further insights into how AMPK inactivation influences tumor progression, we performed Cox regression analyses to determine the association between each of the 71 genes and survival outcomes. The highest number of prognostic genes was observed in glioma; 66 genes (61 good prognoses and five adverse prognoses) (Figure 5B). In contrast, 54 out of 71 genes were associated with adverse prognosis in stomach cancer (Figure 5B). These observations were consistent with the 24-AMPK-gene set being positive and negative prognostic factors in glioma and stomach cancer respectively (Figure 2), which mirrored the behavior of DEGs identified as a result of aberrant AMPK signaling (Figure 4C). Of the 71 genes, only 15 and ten were significantly associated with survival outcomes in sarcoma and breast cancer respectively (Figure 5B). Collectively, our results suggest that the AMPK pathway and its interaction with other signaling modules are key determinants of patient outcomes in multiple cancer types.

Prognostic significance of joint AMPK pathway activity and transcriptional levels of five oncogenic TFs in patients with glioma

Having discovered the importance of the 24-AMPK gene set, we sought to explore the crosstalk between AMPK signaling and TF activity in glioma. As previously mentioned, glioma had the highest 24-AMPK-gene score (Figure 2B) with a vast majority of the genes conferring prognostic information (Figure 2A). Moreover, 66 of the 71 transcriptional targets of the five common TFs identified in patients with altered AMPK signaling were significantly associated with survival outcomes in glioma (Figure 5B). Additionally, TFs FOXM1 and E2F4 were identified to be enriched only in glioma tumors (Figure 4C). Thus, we predict that a joint model uniting AMPK and TF expression profiles would allow further delineation of patients into additional risk groups and if so, allowing combined targeting of AMPK and candidate TFs for therapeutic action. As done previously, we calculated AMPK scores for each patient based on the mean expression of the 24 genes. Interestingly, we found that AMPK scores were significantly negatively correlated with TF expression levels in glioma: E2F4 ($\rho = -0.48$, $P < 0.0001$), EZH2 ($\rho = -0.57$, $P < 0.0001$), FOXM1 ($\rho = -0.49$, $P < 0.0001$), SMAD4 ($\rho = -0.18$, $P < 0.0001$) and SUZ12 ($\rho = -0.23$, $P < 0.0001$) (Figure 6A). We subsequently categorized patients into four groups using the median cutoff of the AMPK scores and TF expression values: 1) low-low, 2) high-high, 3) low AMPK score and






Fig. 6. Prognostic relevance of candidate TFs and the 24-AMPK-gene set in glioma. (A) Scatter plots illustrate significant negative correlations between AMPK scores and TF expression levels in glioma. Patients are separated and color-coded into four categories based on median AMPK and TF scores. Density plots appended to the y- and x-axes demonstrate the distribution of AMPK and TF scores. (B) Log-rank tests are performed on the four patient groups to demonstrate the utility of combined AMPK and TF scores in patient stratification. (C) Univariate Cox regression analyses are performed to compare patient groups where significant P values are highlighted in bold. CI: confidence interval.

high TF expression and 4) high AMPK score and low TF expression. Log-rank tests revealed that patients stratified into the four groups had survival rates that were significantly different: E2F4 ($P < 0.0001$), EZH2 ($P < 0.0001$), FOXM1 ($P < 0.0001$), SMAD4 ($P < 0.0001$) and SUZ12 ($P < 0.0001$) (Figure 6B). For E2F4, EZH2, FOXM1 and SUZ12, patients with low AMPK scores and high TF expression performed the worst: E2F4 (HR = 3.916; $P < 0.0001$), EZH2 (HR = 4.004; $P < 0.0001$), FOXM1 (HR = 5.268; $P < 0.0001$) and SUZ12 (HR = 2.197; $P < 0.0001$) (Figure 6C). For SMAD4, patients within the low-low category had the highest mortality rates (HR = 3.326; $P < 0.0001$) (Figure 6C).

Crosstalk between AMPK and other anabolic-related pathways, PPAR and mTOR

AMPK's anti-anabolic and pro-catabolic activities may work in concert with other metabolic pathways. To investigate the synergistic effects of AMPK and two pro-anabolic pathways, peroxisome proliferator-activated receptors (PPAR) and mammalian target of rapamycin (mTOR) signaling in

tumor progression, we calculated PPAR and mTOR pathway scores (detailed in the methods section) for each glioma tumor. Low AMPK scores were associated with poor outcomes in glioma (Figure 2). To evaluate AMPK and PPAR or mTOR as combined models, patients were separated into four groups using the median cutoff, as mentioned previously. Interestingly, when AMPK and PPAR scores were collectively used for patient stratification, we found that patients with low AMPK and high PPAR scores had the highest death rates (HR = 11.308, $P < 0.0001$), confirming that PPAR hyperactivation is associated with poor outcomes in glioma tumors with low AMPK activity(20) (Figure 7). In contrast, when considering mTOR activity, patients with low AMPK and low mTOR scores performed the worst (HR = 3.023, $P < 0.0001$) (Figure 7). The results overall suggest that the AMPK pathway could act synergistically with PPAR and mTOR signaling to influence cancer progression significantly.




Fig. 7. Crosstalk between AMPK signaling and PPAR or mTOR pathways in glioma. (A) Log-rank tests are performed on patient groups separated into four categories based on median AMPK and PPAR or mTOR scores. (B) Univariate Cox regression analyses are performed to compare patient groups where significant P values are highlighted in bold. CI: confidence interval.

Discussion and Conclusion

While the role of AMPK in energy-sensing is well understood, its full potential in metabolic diseases such as cancer remains an open topic of debate. Despite extensive efforts spent on elucidating the role of AMPK signaling(2, 9, 11), there remains no consensus on whether AMPK promotes or suppresses tumor progression. Exploiting a rich reservoir of pan-cancer datasets afforded to us by TCGA, we performed a thorough examination of genomic and transcriptomic profiles of 92 AMPK pathway genes in diverse cancer types. Our current understanding of AMPK signaling is fueled by genetic studies in cell lines and animal models(2). Although useful in determining causal relationships, results from in vitro cell lines and animal models may have limited translational relevance as they do not accurately reflect human pathology(26). Animal models may offer additional mechanistic insights, but limitations in ethics and costs remain. Moreover, the complexity of human cancers is not accurately modeled in animals; less than 8% of results from animal models are translated to clinical trials(27). Despite analyses on tumor genetic datasets providing mostly correlative outcomes, they remain valuable in understanding disease-specific molecular pathology when interrogated at scale on large patient groups(28), and when results are considered in relation to those obtained from cell lines and animal models.

Employing pan-cancer population data, our study identified

conserved and unique patterns of AMPK signaling across diverse cancer types. Analyses at two molecular levels (genetic and transcriptional) yielded a more comprehensive depiction of AMPK signaling, where we identified genes that were both somatically altered and differentially expressed. These putative loss- or gain-of-function genes are more likely to impact tumor progression as they are altered at both macromolecular levels. As reported in other studies, we confirmed that AMPK signaling could either be oncogenic or tumor suppressive depending on the cellular context. Intuitively, since AMPK is anti-anabolic, its function may not be fitting for tumor growth and proliferation. This is consistent with reports demonstrating AMPK's tumor suppressive activity(29, 30). A study on lymphoma demonstrates that AMPK downregulation induces the Warburg effect and hypoxia signaling in mice(31). AMPK is proposed to act as a metabolic gatekeeper to limit cancer cell division; hence, its loss of function would contribute to tumor aggression because of the loss in metabolic checkpoints(31, 32). AMPK regulates the tumor-suppressive function of the serine/threonine kinase LKB1. Ablation of LKB1 results in enhanced risk of developing gastrointestinal, lung and skin squamous cell cancers(33, 34). Moreover, AMPK is shown to inhibit PI3K/AKT/mTOR signaling, which is activated in many cancers(29, 35). Also, metabolic inhibitors such as metformin, which indirectly activates AMPK could suppress tumor growth via autophagy induc-

tion and mTOR inhibition(29, 36). Metformin is shown to inhibit the proliferation of estrogen receptor α (ER α) negative and positive breast cancer cell lines through AMPK stimulation(37). However, when tested in mice models, metformin contributes to enhanced tumor progression and increased angiogenesis, providing us with a glimpse of potential pro-neoplastic effects of AMPK activation(37).

In our study, we observed that high levels of AMPK pathway activity were associated with better outcomes in glioma, breast cancer and sarcoma (Figure 2); corroborating previous results on the tumor-suppressive function of AMPK. Conversely, the opposite is true in stomach cancer, where AMPK activation contributes to adverse outcomes (Figure 2). It has now been increasingly clear that AMPK activation can also be pro-tumorigenic(12). Double knockout of AMPK α 1 and AMPK α 2 in mouse embryonic fibroblasts result in impaired tumor formation(38). AMPK knockdown in pancreatic cancer cells impairs anchorage-dependent growth and reduces cell viability under glucose deprived conditions(39). AMPK signaling induces cell migration in prostate cancer cells(40) while AMPK knockdown inhibits cell proliferation and promotes apoptosis(41). In liver cancer cells retrieved from primary mouse tumors, AMPK activity is required for Myc-driven carcinogenesis(14). Taken together, these studies suggest that AMPK activation due to metabolic stress within the tumor microenvironment is crucial for the survival of cancerous cells.

Although 19 of the 21 cancers had at least one gain-of-function or loss-of-function gene that correlated with survival outcomes, glioma tumors were most influenced (Figure 2A). The consequence of dysregulated AMPK signaling was further explored in glioma, where the 24-AMPK-gene set and each of the five TFs (identified as regulators of AMPK-associated DEGs) were considered jointly for patient stratification. We observed oncogenic roles of E2F4, EZH2, FOXM1 and SUZ12 – patients with high expression of these TFs had higher mortality rates (Figure 6B). Since the 24-AMPK-gene set was a positive prognostic factor in glioma where high expression of the genes was associated with better outcomes (Figure 2C), glioma patients harboring low AMPK scores and high oncogenic TF scores performed the worst. Our results are confirmed by other reports on the crosstalk between AMPK signaling and E2F4, EZH2, FOXM1 or SUZ12 and their effects on oncogenic progression(42–45). Our analyses on SMAD4 in glioma revealed a likely tumor-suppressive role of the gene (Figure 6B), which is corroborated by another study demonstrating reduced SMAD4 expression during glioma tumor progression(46). When merged with the anti-neoplastic effects of AMPK activation, 5-year survival rates were improved by almost 30% compared to individuals within the low-low category (Figure 6B). SMAD4 protein expression is lost in gastric cancer cells and loss of expression in primary gastric adenocarcinomas are associated with poor survival(47). SMAD4 is also

commonly inactivated in gastrointestinal cancers(48, 49). Restoration of SMAD4 expression in pancreatic cancer cells inhibits tumor function in vivo by influencing angiogenesis through decreased VEGF expression(50).

Our study has demonstrated that there is far from a single unifying role of AMPK signaling in cancer progression. Harnessing multiplatform datasets, this study provides a comprehensive depiction of how AMPK signaling is manifested in a variety of cancers. We anticipate that this repertoire of organized data would be explored by the research community to devise additional research plans aiming to better understand the roles of AMPK in cancer development. We demonstrated that the pro- or anti-neoplastic effects of AMPK activation is cancer-type dependent. Targeting AMPK for treating metabolic diseases such as diabetes has been well established. Also, the potential for targeting AMPK in cancer therapy has been elegantly reviewed(8). However, since AMPK activation is a double-edged sword, careful considerations need to be in place before AMPK can be viably deployed in clinical settings. Our study provides a comprehensive catalog of clinically actionable genetic variations which could be used for patient stratification in prospective clinical trials testing the capabilities of AMPK antagonists or agonists as potential treatments for cancer.

Bibliography

1. David Carling, Victor A Zammit, and D Grahame Hardie. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. *FEBS letters*, 223(2):217–222, 1987.
2. Biplab Dasgupta and Rishi Raj Chhipa. Evolving lessons on the complex role of ampk in normal physiology and cancer. *Trends in pharmacological sciences*, 37(3):192–206, 2016.
3. Simon A Hawley, Jérôme Boudeau, Jennifer L Reid, Kirsty J Mustard, Lina Udd, Tomi P Mäkelä, Dario R Alessi, and D Grahame Hardie. Complexes between the lkb1 tumor suppressor, *strad* α/β and *mo25* α/β are upstream kinases in the amp-activated protein kinase cascade. *Journal of biology*, 2(4):28, 2003.
4. Bruno Guigas, Dominique Detaille, Christiane Chauvin, Cécile Batandier, Frédéric De Oliveira, Eric Fontaine, and Xavier Leverve. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. *Biochemical journal*, 382(3):877–884, 2004.
5. Ryan JO Dowling, Mahvash Zakikhani, I George Fantus, Michael Pollak, and Nahum Sonenberg. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells. *Cancer research*, 67(22):10804–10812, 2007.
6. Deliang Guo, Isabel J Hildebrandt, Robert M Prins, Horacio Soto, Mary M Mazzotta, Julie Dang, Johannes Czernin, John Y-J Shyy, Andrew D Watson, Michael Phelps, et al. The ampk agonist aicar inhibits the growth of egrfiii-expressing glioblastomas by inhibiting lipogenesis. *Proceedings of the National Academy of Sciences*, 106(31):12932–12937, 2009.
7. Antonio F Santidrián, Diana M González-Gironès, Daniel Iglesias-Serret, Llorenç Coll-Mulet, Ana M Cosialls, Mercè de Frias, Clara Campàs, Eva González-Barca, Esther Alonso, Verena Labi, et al. Aicar induces apoptosis independently of ampk and p53 through up-regulation of the bh3-only proteins bim and noxa in chronic lymphocytic leukemia cells. *Blood*, 116(16):3023–3032, 2010.
8. Weidong Li, Shakir M Saud, Matthew R Young, Guohong Chen, and Baojin Hua. Targeting ampk for cancer prevention and treatment. *Oncotarget*, 6(10):7365, 2015.
9. Sang-Min Jeon and Nissim Hay. The dark face of ampk as an essential tumor promoter. *Cellular logistics*, 2(4):197–202, 2012.
10. D Grahame Hardie and Dario R Alessi. Lkb1 and ampk and the cancer-metabolism link-ten years after. *BMC biology*, 11(1):36, 2013.
11. Jiyong Liang and Gordon B Mills. Ampk: a contextual oncogene or tumor suppressor? *Cancer research*, 73(10):2929–2935, 2013.
12. Brandon Faubert, Emma E Vincent, Maya C Poffenberger, and Russell G Jones. The amp-activated protein kinase (ampk) and cancer: many faces of a metabolic regulator. *Cancer letters*, 356(2):165–170, 2015.
13. Sarit Mizrahy-Schwartz, Noam Cohen, Shoshana Klein, Nataly Kravchenko-Balasha, and Alexander Levitzki. Up-regulation of amp-activated protein kinase in cancer cell lines is mediated through c-src activation. *Journal of Biological Chemistry*, 286(17):15268–15277, 2011.
14. Lidan Liu, Jannes Ulbrich, Judith Müller, Torsten Wüstefeld, Lukas Aeberhard, Theresia R Kress, Nathiya Muthalagu, Lukas Rycak, Ramona Rudalska, Roland Moll, et al. Deregulated myc expression induces dependence upon ampk-related kinase 5. *Nature*, 483(7391):608, 2012.

15. Marcos Ríos, Marc Foretz, Benoit Viollet, Angel Prieto, Máximo Fraga, Jose A Costoya, and Rosa Señaris. Ampk activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. *Cancer research*, 73(8):2628–2638, 2013.
16. Elite Possik, Zahra Jalali, Yann Nouët, Ming Yan, Marie-Claude Gingras, Kathrin Schmeisser, Lorena Panaite, Fanny Dupuy, Dmitri Kharitidi, Laëticia Chotard, et al. Follistatin regulates ampk-dependent autophagy and metabolic stress survival. *PLoS genetics*, 10(4):e1004273, 2014.
17. Ming Yan, Marie-Claude Gingras, Elaine A Dunlop, Yann Nouët, Fanny Dupuy, Zahra Jalali, Elite Possik, Barry J Coull, Dmitri Kharitidi, Anders Bondo Dydensborg, et al. The tumor suppressor follistatin regulates ampk-dependent metabolic transformation. *The Journal of clinical investigation*, 124(6):2640–2650, 2014.
18. John N Weinstein, Eric A Collisson, Gordon B Mills, Kenna R Mills Shaw, Brad A Ozenberger, Kyle Ellrott, Ilya Shmulevich, Chris Sander, Joshua M Stuart, Cancer Genome Atlas Research Network, and Others. The cancer genome atlas pan-cancer analysis project. *Nature genetics*, 45(10):1113, 2013.
19. Wai Hoong Chang, Donall Forde, and Alvina G Lai. A novel signature derived from immunoregulatory and hypoxia genes predicts prognosis in liver and five other cancers. *Journal of translational medicine*, 17(1):14, jan 2019. ISSN 1479-5876. doi: 10.1186/s12967-019-1775-9.
20. Wai Hoong Chang and Alvina G Lai. The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia. *Annals of the New York Academy of Sciences*, 1448(1):65–82, jul 2019. ISSN 1749-6632. doi: 10.1111/nyas.14170.
21. Craig H Mermel, Steven E Schumacher, Barbara Hill, Matthew L Meyerson, Rameen Beroukhi, and Gad Getz. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome biology*, 12(4):R41, 2011.
22. Jüri Reimand, Meelis Kull, Hedi Peterson, Jaanus Hansen, and Jaak Vilo. g: Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments. *Nucleic acids research*, 35(suppl_2):W193–W200, 2007.
23. Edward Y Chen, Christopher M Tan, Yan Kou, Qiaonan Duan, Zichen Wang, Gabriela Vaz Meirelles, Neil R Clark, and Avi Ma'ayan. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC bioinformatics*, 14(1):128, 2013.
24. Maxim V Kuleshov, Matthew R Jones, Andrew D Rouillard, Nicolas F Fernandez, Qiaonan Duan, Zichen Wang, Simon Koplev, Sherry L Jenkins, Kathleen M Jagodnik, Alexander Lachmann, and Others. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic acids research*, 44(W1):W90–W97, 2016.
25. Chad J Creighton, Xiaoyong Fu, Bryan T Hennessy, Angelo J Casa, Yiqun Zhang, Ana Maria Gonzalez-Angulo, Ana Lluch, Joe W Gray, Powell H Brown, Susan G Hilsenbeck, and Others. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. *Breast cancer research*, 12(3):R40, 2010.
26. Sheng Guo, Wubin Qian, Jie Cai, Likun Zhang, Jean Pierre Wery, and Qi Xiang Li. Molecular pathology of patient tumors, patient-derived xenografts, and cancer cell lines. *Cancer Research*, 76(16):4619–4626, 2016. ISSN 15387445. doi: 10.1158/0008-5472.CAN-15-3245.
27. Isabella WY Mak, Nathan Evaniew, and Michelle Ghert. Lost in translation: animal models and clinical trials in cancer treatment. *American journal of translational research*, 6(2):114, 2014.
28. Anil Korkut, Sobia Zaidi, Rupa S Kanchi, Shuyun Rao, Nancy R Gough, Andre Schultz, Kubin Li, Philip L Lorenzi, Ashton C Berger, Gordon Robertson, Lawrence N Kwong, Mike Datto, Jason Roszik, Shiyun Ling, Visweswaran Ravikumar, Ganiraju Manyam, Arvind Rao, Simon Shelley, Yuxin Liu, Zhenlin Ju, Donna Hansel, Guillermo de Velasco, Arjun Pen-nathur, Jesper B Andersen, Colm J O'Rourke, Kazufumi Ohshiro, Wilma Jogunoori, Bao-Ngoc Nguyen, Shulin Li, Hatice U Osmanbeyoglu, Jaffer A Ajani, Sendurai A Mani, Andres Houseman, Maciej Wiznerowicz, Jian Chen, Shoujun Gu, Wencai Ma, Jiexin Zhang, Pan Tong, Andrew D Cherniack, Chuxia Deng, Linda Resar, Cancer Genome Atlas Research Network, John N Weinstein, Lopa Mishra, and Rehan Akbani. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. *Cell systems*, 7(4):422–437, oct 2018. ISSN 2405-4712. doi: 10.1016/j.cels.2018.08.010.
29. David B Shackelford and Reuben J Shaw. The lkb1—ampk pathway: metabolism and growth control in tumour suppression. *Nature Reviews Cancer*, 9(8):563, 2009.
30. D Grahame Hardie. Amp-activated protein kinase—an energy sensor that regulates all aspects of cell function. *Genes & development*, 25(18):1895–1908, 2011.
31. Brandon Faubert, Gino Boily, Said Izreig, Takla Griss, Bozena Samborska, Zhifeng Dong, Fanny Dupuy, Christopher Chambers, Benjamin J Fuerth, Benoit Viollet, et al. Ampk is a negative regulator of the warburg effect and suppresses tumor growth in vivo. *Cell metabolism*, 17(1):113–124, 2013.
32. Zhijun Luo, Mengwei Zang, and Wen Guo. Ampk as a metabolic tumor suppressor: control of metabolism and cell growth. *Future oncology*, 6(3):457–470, 2010.
33. Dario R Alessi, Kei Sakamoto, and Jose R Bayascas. Lkb1-dependent signaling pathways. *Annu. Rev. Biochem.*, 75:137–163, 2006.
34. Sushma Gurumurthy, Aram F Hezel, Justin H Berger, Marcus W Bosenberg, and Nabeel Bardeesy. Lkb1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. *Cancer Research*, 68(1):55–63, 2008.
35. Yiqun Zhang, Patrick Kwok-shing Ng, Melanie Kuchertapati, Gordon B Mills, David J Kwiatkowski, and Chad J Creighton. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. *Cancer Cell*, 31:820–832, 2017. doi: 10.1016/j.ccell.2017.04.013.
36. WY Shi, D Xiao, L Wang, LH Dong, ZX Yan, ZX Shen, SJ Chen, Y Chen, and WL Zhao. Therapeutic metformin/ampk activation blocked lymphoma cell growth via inhibition of mtor pathway and induction of autophagy. *Cell death & disease*, 3(3):e275, 2012.
37. Kathryn N Phoenix, Frank Vumbaca, and Kevin P Claffey. Therapeutic metformin/ampk activation promotes the angiogenic phenotype in the *er α* negative mda-mb-435 breast cancer model. *Breast cancer research and treatment*, 113(1):101–111, 2009.
38. Keith R Laderoute, Khalid Amin, Joy M Calaoagan, Merrill Knapp, Theresamai Le, Juan Orduña, Marc Foretz, and Benoit Viollet. 5-amp-activated protein kinase (ampk) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. *Molecular and cellular biology*, 26(14):5336–5347, 2006.
39. Kazuyoshi Kato, Tsutomu Ogura, Atsuhiko Kishimoto, Yuji Minegishi, Nobuyuki Nakajima, Masaru Miyazaki, and Hiroyasu Esumi. Critical roles of amp-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. *Oncogene*, 21(39):6082, 2002.
40. Daniel E Frigo, Matthew K Howe, Bryan M Wittmann, Abigail M Brunner, Ian Cushman, Qianben Wang, Myles Brown, Anthony R Means, and Donald P McDonnell. Cam kinase kinase β -mediated activation of the growth regulatory kinase ampk is required for androgen-dependent migration of prostate cancer cells. *Cancer research*, 71(2):528–537, 2011.
41. Hyeon Ung Park, Simeng Suy, Malika Danner, Vernon Dailey, Ying Zhang, Henghong Li, Daniel R Hyde, Brian T Collins, Gregory Gagnon, Bhaskar Kallakury, et al. Amp-activated protein kinase promotes human prostate cancer cell growth and survival. *Molecular cancer therapeutics*, 8(4):733–741, 2009.
42. Mingo Ming Ho Yung, David Wai Chan, Vincent Wing Sun Liu, Kwok-Ming Yao, and Hex-tan Yuen-Sheung Ngan. Activation of ampk inhibits cervical cancer cell growth through akt/foxo3a/foxm1 signaling cascade. *BMC cancer*, 13(1):327, 2013.
43. Dong Hao Jin, Yujin Kim, Bo Bin Lee, Joungho Han, Hong Kwan Kim, Young Mog Shim, and Duk-Hwan Kim. Metformin induces cell cycle arrest at the g1 phase through e2f8 suppression in lung cancer cells. *Oncotarget*, 8(60):101509, 2017.
44. Jae Hee Lee, Hyo-Jung Lee, Deok Yong Sim, Ji Hoon Jung, Ka Ram Kim, and Sung-Hoon Kim. Apoptotic effect of lamberianic acid through ampk/foxm1 signaling in mda-mb231 breast cancer cells. *Phytotherapy research*, 32(9):1755–1763, 2018.
45. Lixin Wan, Kexin Xu, Yongkun Wei, Jinfang Zhang, Tao Han, Christopher Fry, Zhao Zhang, Yao Vickie Wang, Liyu Huang, Min Yuan, et al. Phosphorylation of ezh2 by ampk suppresses prc2 methyltransferase activity and oncogenic function. *Molecular cell*, 69(2):279–291, 2018.
46. Shi-ming He, Zhen-wei Zhao, Yuan Wang, Ji-pei Zhao, Liang Wang, Fang Hou, and Guo-dong Gao. Reduced expression of smad4 in gliomas correlates with progression and survival of patients. *Journal of Experimental & Clinical Cancer Research*, 30(1):70, 2011.
47. Li-Hui Wang, Seok-Hyung Kim, Jung Hyun Lee, Yoon-La Choi, Young Chul Kim, Tae Sung Park, Yun-Chul Hong, Chun-Fu Wu, and Young Kee Shin. Inactivation of smad4 tumor suppressor gene during gastric carcinoma progression. *Clinical cancer research*, 13(1):102–110, 2007.
48. YUKIHIRO Takagi, HISASHI Kohmura, MANABU Futamura, HISASHI Kida, HIROMI Tanemura, KUNYASU Shimokawa, and SHIGETOYO Saji. Somatic alterations of the dpc4 gene in human colorectal cancers in vivo. *Gastroenterology*, 111(5):1369–1372, 1996.
49. Detlef Bartsch, Stephan A Hahn, Kirill D Danichevski, Annette Ramaswamy, Daniel Bastian, Hamid Galehdari, Peter Barth, Wolff Schmiegell, Babette Simon, and Matthias Rothmund. Mutations of the dpc4/sm4 gene in neuroendocrine pancreatic tumors. *Oncogene*, 18(14):2367, 1999.
50. Irmgard Schwarte-Waldhoff, Olga V Volpert, Noël P Bouck, Bence Sipos, Stephan A Hahn, Susanne Klein-Scory, Jutta Lüttges, Günter Klöppel, Ulrich Graeven, Christina Eilert-Micus, et al. Smad4/dpc4-mediated tumor suppression through suppression of angiogenesis. *Proceedings of the National Academy of Sciences*, 97(17):9624–9629, 2000.